Sanofi Alliance Is Big Boost For Company Behind Type 1 Diabetes Prevention Drug

Provention’s Therapy Delays Onset By Three Years

 
• By Andrew McConaghie

Sanofi has deprioritized its presence in type 1 diabetes in recent years but could help turn teplizumab into a game-changer blockbuster product.

Sanofi logo
Sanofi has exited Type 1 diabetes research, but retains a large commercial infrastructure in the US and worldwide. • Source: Shutterstock

More from Business

More from Scrip